Advertisement


Martin H. Schuler, MD, on Gastric and GEJ Adenocarcinoma: Results of the FAST Study (German Language Version)

2016 ESMO Congress

Advertisement

Martin H. Schuler, MD, of the University Hospital Essen, discusses in German findings from this phase II trial of epirubicin, oxaliplatin, and capecitabine with or without the antibody IMAB362 as first-line therapy in patients with advanced CLDN18.2+ disease. (Abstract 614O)



Related Videos

Multiple Myeloma

Katja Weisel, MD, on Multiple Myeloma: Results of the CASTOR Study

Katja Weisel, MD, of the University of Tübingen, discusses study findings on daratumumab, bortezomib, and dexamethasone vs bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma. (Abstract 906O)

Skin Cancer

Paolo A. Ascierto, MD, on Metastatic Melanoma: Ipilimumab Study Results (Italian Language Version)

Paolo A. Ascierto, MD, of the Istituto Nazionale Tumori–Fondazione Pascale, discusses in Italian overall survival and safety results from a phase 3 trial of ipilimumab at 3 mg/kg vs 10 mg/kg in patients with metastatic melanoma. (Abstract 1106O)

Breast Cancer

Matthew J. Ellis, PhD, MB, BCh, on Breast Cancer: Results of the FALCON Trial

Matthew J. Ellis, PhD, MB, BCh, of the Baylor College of Medicine, discusses phase III study findings on fulvestrant 500 mg vs anastrozole for hormone receptor-positive advanced disease. (Abstract LBA14)

Breast Cancer

Sara A. Hurvitz, MD, on Breast Cancer: Results From the neoMONARCH Trial

Sara A. Hurvitz, MD, of the University of California, Los Angeles, discusses interim findings on abemaciclib in postmenopausal women with HR+/HER2- breast cancer. (Abstract LBA13)

Lung Cancer

Tony Mok, MD, on NSCLC: Results of the IMPRESS Study

Tony Mok, MD, of The Chinese University of Hong Kong, discusses the final overall survival analysis from this trial on gefitinib/chemotherapy vs chemotherapy in EGFR mutation-positive non-small cell lung cancer after progression on first-line gefitinib. (Abstr 1201O)

Advertisement

Advertisement




Advertisement